Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (381-390 of 713) with videos related to

Pageof 72
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2011
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Jorge Cortes, Alfonso Quintas-Cardama, Elias Jabbour, et al.
Leukemia Research|April 28, 2004
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcomeAnne S Tsao, Hagop Kantarjian, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisAlfonso Quintás-Cardama, Hagop M Kantarjian, Taghi Manshouri, et al.
Cancer|June 19, 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trialNitin Jain, James M Reuben, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndromeHady Ghanem, A Megan Cornelison, Guillermo Garcia-Manero, et al.
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Therapeutic Advances in Hematology|April 2, 2014
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failureHady Ghanem, Guillermo Garcia-Manero, Stefan Faderl, et al.
Hematology Reports|February 25, 2025
The Role of Ferritin and Folate in Determining Stem Cell Collection for Autologous Stem Cell Transplant in Multiple MyelomaCharles J Weeks, Mohammad Mian, Michael Stokes, et al.
Blood|July 31, 2013
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemiaKoichi Takahashi, Naveen Pemmaraju, Paolo Strati, et al.
Haematologica|October 15, 2020
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosisMahran Shoukier, Gautam Borthakur, Elias Jabbour, et al.
Pageof 72

Showing results (381-390 of 713) with videos related to

Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2011
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Jorge Cortes, Alfonso Quintas-Cardama, Elias Jabbour, et al.
Leukemia Research|April 28, 2004
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcomeAnne S Tsao, Hagop Kantarjian, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisAlfonso Quintás-Cardama, Hagop M Kantarjian, Taghi Manshouri, et al.
Cancer|June 19, 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trialNitin Jain, James M Reuben, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndromeHady Ghanem, A Megan Cornelison, Guillermo Garcia-Manero, et al.
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Therapeutic Advances in Hematology|April 2, 2014
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failureHady Ghanem, Guillermo Garcia-Manero, Stefan Faderl, et al.
Hematology Reports|February 25, 2025
The Role of Ferritin and Folate in Determining Stem Cell Collection for Autologous Stem Cell Transplant in Multiple MyelomaCharles J Weeks, Mohammad Mian, Michael Stokes, et al.
Blood|July 31, 2013
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemiaKoichi Takahashi, Naveen Pemmaraju, Paolo Strati, et al.
Haematologica|October 15, 2020
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosisMahran Shoukier, Gautam Borthakur, Elias Jabbour, et al.
Pageof 72